drugset
drugset / Trial / NCT05787860

Ruxolitinib in Seborrheic Dermatitis

NCT05787860 ↗

Phase 2 Completed 45 enrolled Icahn School of Medicine at Mount Sinai Incyte Corporation · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is an open-label prospective interventional trial that will assess the efficacy of ruxolitinib in the treatment of seborrheic dermatitis. It will also attempt to characterize the molecular immune profiles of patients with SD at week 0 and week 4, with comparison to baseline profiles in healthy control subjects.

Timeline

Start
2022-11-15
Primary completion
2024-01-26
Completion
2024-01-26

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ruxolitinib Small molecule 1.5 % Topical

Indications

seborrheic dermatitis